drugset / Trial / NCT04846634
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
Phase 2
Not yet recruiting
90 enrolled
Tianjin Medical University Cancer Institute and Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, randomized, open label, phase II study.
Timeline
- Start
- 2021-08
- Primary completion
- 2023-03
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |